How It Works

A research process built
around your case, not a template.

From your first message to the final intelligence brief, every step is designed to extract the maximum signal from your medical situation — and translate it into options your care team can act on.

01 Submit 02 Research 03 Report 04 Support

Step 01

Submit Your Case

Everything begins with a conversation. Submit your case through the contact form or reach out directly by email — no intake questionnaire, no portal to navigate, no automated triage system.

Within 24 hours, you will receive a response with a link to schedule a free 20-minute intake call. This call has one purpose: to understand your situation well enough to confirm that EviGeno can add genuine value, and to agree on the scope of the research before any payment is made.

No case is taken on unless we believe the research will be meaningful. If your situation is better served by a different resource, we will tell you plainly and point you in the right direction.

What to share in your first message

Your diagnosis and disease stage
What treatments you have already tried
Whether you have NGS or genomic testing results
What you are hoping to find out

Free Intake Call

20 min
Understand your case in depth
Confirm scope and fit
No payment until after this call

Response within 24 hours

Every message reviewed personally

01

Sources searched for every case

ClinicalTrials.gov US
EU Clinical Trials Register EU
WHO ICTRP Global
Regional registries Asia / LATAM
FDA / EMA regulatory filings Regulatory
PubMed / scientific literature Literature
ClinVar / cBioPortal / COSMIC Genomic
Biopharma pipeline intelligence Industry
Expanded access / compassionate use Access

Every source is searched with your specific molecular profile, disease stage, and eligibility criteria — not as a generic query.

02

Step 02

Deep-Case Research

Once the intake call is complete and scope is agreed, the research begins. This is a structured OSINT-driven process — not a keyword search across one or two databases, but a systematic sweep across every relevant source we can access.

We work from your molecular profile outward: starting with the specific mutations, biomarkers, and disease characteristics that define your case, then mapping what the global treatment and trial landscape looks like for that exact profile. Sources that require domain expertise to interpret — genomic databases, regulatory approval documents, industry pipeline filings — are read and assessed directly, not summarized by an algorithm.

Every option identified is assessed for relevance and eligibility against your specific situation before it appears in the report. We do not include options that look plausible on the surface but would not survive clinical scrutiny.

Molecular-first approach: Research is anchored to your specific biomarkers and genomic profile, not your diagnosis category alone

Multi-registry sweep: Every major trial registry plus regional and non-English sources that Western tools routinely miss

Eligibility pre-screening: Every trial is checked against your profile before inclusion — no false leads

Step 03

Intelligence Report

The research is compiled into a structured written brief — designed to be read by both patients and their clinical teams. It is not a list of links or a printout of search results. It is a synthesized, annotated document that explains what was found, why it is relevant to your case, and what the next steps might be.

Every option in the report is accompanied by enough context for your oncologist or specialist to evaluate it immediately — trial phase, eligibility criteria, mechanism of action, and access pathway. Nothing is included without a clear rationale tied to your specific profile.

The report is delivered as a PDF within 5–7 business days of intake confirmation. A 30-minute follow-up call is included to walk through findings, answer questions, and discuss next steps.

5–7 business days
Delivered as PDF
Follow-up call included

Report structure

01 Case Summary

Diagnosis, molecular profile, treatment history, research objectives

02 Approved Therapy Landscape

FDA / EMA / international approvals matched to your subtype and biomarkers

03 Clinical Trial Matches

Active trials globally with eligibility assessment, phase, location, and contact

04 Off-Label & Investigational Options

Evidence-supported off-label uses and pipeline agents with access pathway notes

05 Specialist & Center Identification

Most relevant experts and institutions worldwide for your specific case

06 Recommended Next Steps

Prioritized action items for you and your care team based on findings

03

What gets monitored monthly

New trial openings

Trials that open enrollment and match your eligibility profile

Regulatory decisions

New approvals, label expansions, or accelerated designations relevant to your case

Pipeline developments

Investigational agents advancing through Phase II/III that may become accessible

Enrollment & specialist outreach

Active support contacting trial sites and preparing case summaries for eligibility review

24-hour urgent response

Time-sensitive questions answered within 24 hours for retainer clients

Month-to-month — cancel or pause anytime, no penalty
04

Step 04

Ongoing Support

A single report captures the landscape at one point in time. For patients in active treatment or pursuing trial enrollment, the intelligence environment shifts continuously — new trials open, regulatory decisions land, pipeline molecules advance or fail.

Monthly retainer clients receive continuous coverage: we monitor everything relevant to your case on an ongoing basis and surface new developments as they emerge — before your next appointment, not after.

This is the level of support appropriate for cases where timing matters — where a trial that opens today may close in six weeks, or where a regulatory decision this quarter changes what is accessible to you.

Starting with a single report?

Many clients begin with an Intelligence Report to understand the landscape, then move to the monthly retainer when they enter an active decision period. The transition is seamless — your case file carries forward with no duplication of work.

What to Expect

From first contact to report delivery

A typical engagement runs 7–10 business days. Complex cases with extensive genomic data may take longer — scope and timeline are confirmed before any work begins.

1
Day 0–1
Intake & Scoping

You submit your case. We review your records, confirm scope, and agree on deliverables and timeline.

2
Day 2–5
Deep Research

Systematic search across global registries, regulatory databases, and pipeline sources — matched to your molecular profile.

3
Day 5–7
Report Delivery

A structured intelligence report, ready to share with your care team. A walkthrough call is included to answer questions.

+
Ongoing
Retainer Support

Optional monthly coverage — new trials, regulatory changes, and pipeline developments surfaced as they happen.

No payment before scoping. Every engagement begins with a free 20-minute intake call. Scope, timeline, and fee are agreed before any work starts. If we can't add value to your case, we'll tell you.

Get Started

Your case deserves
a complete picture.

Start with a free 20-minute intake call. No payment, no commitment — just a conversation to understand your case and confirm we can help.

We respond within 24 hours

Every inquiry is reviewed personally — no automated responses

Free 20-min intake call before any payment

We confirm fit before you commit to anything

Report delivered in 5–7 business days

Scope and timeline confirmed upfront for complex cases

Or reach out directly

[email protected]

Submit your case

We'll review your situation and be in touch within 24 hours.

Your information is kept strictly confidential and used only to respond to your inquiry. EviGeno does not share or sell personal data.